Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28921225 | 0.79 | MAPT (0.47) | HSPB1LMNAPOLBMAPTL3MBTL1 | |
| SCHEMBL22190310 | 0.79 | EPAS1 (0.40) | EPAS1 | |
| SCHEMBL22203241 | 0.79 | SLC6A4 (0.39) | — | |
| SCHEMBL7091398 | 0.78 | MAPT (0.47) | HSPB1LMNAPOLBMAPTCCR6 | |
| SCHEMBL22203245 | 0.77 | SCN8A (0.45) | — | |
| SCHEMBL22203239 | 0.77 | SCN8A (0.45) | — | |
| SCHEMBL29435962 | 0.77 | SCN8A (0.45) | — | |
| SCHEMBL29435931 | 0.77 | SCN8A (0.45) | — | |
| SCHEMBL4475384 | 0.76 | LMNA (0.44) | LMNAMAPTHPGD | |
| SCHEMBL15329644 | 0.76 | LMNA (0.46) | HSPB1LMNAPOLBSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112955436-B | 6-oxo-1, 6-dihydropyridazine derivatives, preparation method and application thereof in medicines | 福建盛迪医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20220073471-A1 | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2022-03-10 | — | — | US | disclosed |
| CN-112955436-A | 6-oxo-1, 6-dihydropyridazine derivatives, preparation method and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073471-A1 | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CACNA1D, CACNA1F, CACNA1B | HSPB1 3261/4885LMNA 1886/4885POLB 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.